The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC/IF: Use at a concentration of 10 - 20 µg/ml.
IP: Use at a concentration of 5 - 10 µg.
WB: Use at a concentration of 2 - 5 µg/ml. Predicted molecular weight: 27 kDa.
Detection of the band by immunoblotting is specifically inhibited by the immunizing peptide.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionFunctional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal glycoproteins, but not that of misfolded nonglycoproteins. May act by forming a channel that allows the retrotranslocation of misfolded glycoproteins into the cytosol where they are ubiquitinated and degraded by the proteasome. May mediate the interaction between VCP and the degradation substrate.
Tissue specificityUnlike DERL1 and DERL2, restricted to several tissues. Expressed at high levels in placenta, pancreas, spleen and small intestine.
Sequence similaritiesBelongs to the derlin family.